FDA approved drugs:
| # |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
| 1 |
|
Cervarix
18
49
|
Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant |
GlaxoSmithKline |
October 2009 |
Disease/s that Drug Treats:prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18
Indications and Usage:
18
DrugBank Targets:
-
Mechanism of Action:
18
Target: IgG neutralizing antibodies directed against HPV-L1 capsid proteins
Action: activates/ provokes production
FDA: -
|
| 2 |
|
Gardasil
18
49
|
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine |
Merck |
June 2006 |
Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus
Indications and Usage:
18
GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7)
DrugBank Targets:
-
Mechanism of Action:
18
Target: humoral immune response
Action: inducer
FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.
|
Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 27)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Vaccines |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 2 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 3 |
|
21645-51-2 |
|
|
Synonyms:
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
Aluminum hydroxide gel, dried
|
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
|
|
| 3 |
|
Immunologic Factors |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 4 |
|
Immunoglobulins |
|
Phase 3,Phase 2 |
|
|
|
| 5 |
|
Antibodies |
|
Phase 3,Phase 2 |
|
|
|
| 6 |
|
Antacids |
|
Phase 3 |
|
|
|
| 7 |
|
Anti-Ulcer Agents |
|
Phase 3 |
|
|
|
| 8 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
| 9 |
|
Gastrointestinal Agents |
|
Phase 3 |
|
|
|
| 10 |
|
Metformin |
Approved |
Phase 2 |
|
657-24-9 |
14219
4091
|
|
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
cMAP_000016
D04966
DB00331
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMGG
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
Haurymelin
HMS2089D19
HSCI1_000295
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
|
KBioSS_002312
LA-6023
LS-43899
Melbin
metformin
Metformin
Metformin (USAN/INN)
Metformin [USAN:INN:BAN]
Metformin HCL
metformin hydrochloride
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
Sandoz Metformin
Siofor
SPBio_001928
STK011633
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
|
|
| 11 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
|
Synonyms:
|
| 12 |
|
Testosterone |
Approved, Investigational |
Phase 1, Phase 2 |
|
58-22-0 |
6013
|
|
Synonyms:
(17beta)-17-Hydroxyandrost-4-en-3-one
(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
17 alpha Testosterone
17?-Hydroxy-4-androsten-3-one
17a-cis-Testosterone
17-alpha-Testosterone
17beta-Hydroxy-3-oxo-4-androstene
17beta-hydroxy-4-androsten-3-one
17beta-Hydroxy-4-androsten-3-one
17beta-Hydroxyandrost-4-en-3-one
17-beta-Hydroxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-ene-3-one
17-beta-Hydroxy-delta(sup 4)-androsten-3-one
17beta-Hydroxy-delta(sup4)-androsten-3-one
17b-hydroxy-4-androsten-3-one
17-Epitestosterone
17-Hydroxy-(17beta)-androst-4-en-3-one
17-Hydroxy-(17-beta)-androst-4-en-3-one
46923_FLUKA
46923_RIEDEL
4-Androsten-17?-ol-3-one
4-Androsten-17beta-ol-3-one
4-androsten-17β-ol-3-one
4-androstene-17beta-ol-3-one
58-22-0
7-beta-Hydroxyandrost-4-en-3-one
AA 2500
AC-14899
AC1L1LM0
Andriol
Andro
Andro 100
Andro L.A. 200
Androderm
Androderm (TN)
Androgel
AndroGel
Androgel (TN)
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
Andropatch
Andropository 200
Androsorb
Androst-4-en-17beta-ol-3-one
Andrusol
Andryl 200
B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E
beta testosterone
Beta Testosterone
BIDD:ER0555
BIM-0061761.0001
Bio-0678
Bio-T-Gel
C00535
CCRIS 574
CDB 111C
CHEBI:17347
CHEMBL386630
CID6013
cis-Testosterone
CMC_13449
COL 1621
CP 601B
CPD000058344
Cristerona T
Cristerone T
D00075
DB00624
Dea No. 4000
Delatest
Delatestryl
delta(sup 4)-Androsten-17(beta)-ol-3-one
delta4-Androsten-17beta-ol-3-one
delta4-androsten-17b-ol-3-one
Depotest
Depo-Testosterone
Depo-Testosterone Cypionate
EINECS 200-370-5
Epi-testosterone
Everone 200
Geno-cristaux gremy
Geno-Cristaux Gremy
Halotensin
HMS2052N11
Homosteron
Homosterone
HSDB 3398
Intrinsa
Isotestosterone
Libigel
LibiGel
LMST02020002
LS-148813
Malerone
|
Malestrone
Malestrone (amps)
Malogen in Oil
Malogen, aquaspension injection
Malogen, Aquaspension Injection
Mertestate
Metandren
Methyltestosterone
MLS000563091
MLS001032098
MLS001306401
MLS002174283
MolPort-002-506-901
NCGC00091018-01
Neo-Hombreol F
Neotestis
Neo-testis
Neo-Testis
NSC 9700
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Perandren
Percutacrine androgenique
Percutacrine Androgenique
Primotest
Primoteston
Relibra
S00309
S2033_Selleck
SAM001246921
Scheinpharm Testone-Cyp
SMR000058344
SMR001261453
Striant
Striant (TN)
Sustanon
Sustanone
Sustason 250
Synandrol F
T1500_SIGMA
T5411_FLUKA
T5411_SIGMA
T-Cypionate
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
Testim
Testim (TN)
Testobase
Testoderm
Testoderm Tts
Testogel
Testoject-50
Testolin
Testopel Pellets
Testopropon
Testosteroid
Testosteron
Testosterona
Testosterona [INN-Spanish]
testosterone
Testosterone
Testostérone
Testosterone (JAN/USP)
Testosterone [Androgenic steroids, anabolic]
Testosterone [INN:BAN]
Testosterone and its esters
Testosterone Cypionate
Testosterone Enanthate
Testosterone hydrate
Testosterone Hydrate
Testosterone solution
Testosteronum
Testosteronum [INN-Latin]
Testostosterone
Testoviron
Testoviron Schering
Testoviron T
Testred
Testred Cypionate 200
Testrin-P.A
Testro Aq
Testro AQ
Testrone
Testryl
trans-Testosterone
Trans-Testosterone
UNII-3XMK78S47O
Virilon
Virilon IM
Virormone
Virosterone
ZINC06500184
|
|
| 13 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 1, Phase 2 |
|
6055-19-2, 50-18-0 |
2907
|
|
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
|
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Ledoxina
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
| 14 |
|
Hypoglycemic Agents |
|
Phase 2 |
|
|
|
| 15 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
| 16 |
|
Alkylating Agents |
|
Phase 1, Phase 2 |
|
|
|
| 17 |
|
Hormones |
|
Phase 1, Phase 2 |
|
|
|
| 18 |
|
Immunosuppressive Agents |
|
Phase 1, Phase 2 |
|
|
|
| 19 |
|
Antineoplastic Agents, Alkylating |
|
Phase 1, Phase 2 |
|
|
|
| 20 |
|
Androgens |
|
Phase 1, Phase 2 |
|
|
|
| 21 |
|
Hormone Antagonists |
|
Phase 1, Phase 2 |
|
|
|
| 22 |
|
Antirheumatic Agents |
|
Phase 1, Phase 2 |
|
|
|
| 23 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 1, Phase 2 |
|
|
|
| 24 |
|
Proflavine |
Approved |
Not Applicable |
|
92-62-6 |
7099
|
|
Synonyms:
1811-28-5
1bcu
1qvt
1qvu
2,8-Diaminoacridine
2,8-Diaminoacridine (European)
2,8-Diaminoacridinium
3,6 diamino Acridine
3,6 Diaminoacridine
3,6 -Diaminoacridine sulfate
3,6-acridinediamine
3,6-Acridinediamine
3,6-ACRIDINEDIAMINE
3,6-Acridinediamine hydrochloride
3,6-diamino Acridine
3,6-diaminoacridine
3,6-Diaminoacridine
3,6-Diaminoacridinium
3,6-Diamino-acridinium
3,7-Diamino-5-azaanthracene
5-22-11-00322 (Beilstein Handbook Reference)
92-62-6
952-23-8
AC1L1O07
AC1Q52G9
AC1Q52GA
Acridine, 3,6-diamino
acridine-3,6-diamine
AE-562/12222295
AI3-52128
BRN 0166050
C11181
C13H11N3
CCRIS 1244
CHEBI:45272
|
CHEBI:8452
CHEMBL55400
CID7099
DB01123
Diaminoacridine
EINECS 202-172-4
Hemisulfate, proflavine
HSDB 7071
InChI=1/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2
Isoflav base
LS-14311
MolPort-001-790-988
NCGC00166245-01
NCI60_004643
NCI60_004767
NCI60_032077
NCIMech_000209
PF
PRL
Proflavin
Proflavina
Proflavina [INN-Spanish]
Proflavine
Proflavine [INN]
Proflavine hemisulfate
Proflavine Hemi-Sulfate
Proflavinum
Proflavinum [INN-Latin]
Profoliol-B
Profura
Progarmed
STK380650
UNII-CY3RNB3K4T
ZINC03775644
|
|
| 25 |
|
Anti-Infective Agents |
|
Not Applicable |
|
|
|
| 26 |
|
Anti-Infective Agents, Local |
|
Not Applicable |
|
|
|
| 27 |
|
Pharmaceutical Solutions |
|
Not Applicable |
|
|
|
Interventional clinical trials:
(show all 35)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) |
Completed |
NCT01544478
|
Phase 4 |
|
| 2 |
Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO) |
Unknown status |
NCT01429649
|
Phase 3 |
|
| 3 |
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants |
Completed |
NCT00128661
|
Phase 3 |
|
| 4 |
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) |
Completed |
NCT00092521
|
Phase 3 |
|
| 5 |
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) |
Completed |
NCT00834106
|
Phase 3 |
|
| 6 |
Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects |
Completed |
NCT00779766
|
Phase 3 |
|
| 7 |
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 |
Completed |
NCT00122681
|
Phase 3 |
|
| 8 |
Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study |
Completed |
NCT00929526
|
Phase 3 |
|
| 9 |
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older |
Completed |
NCT00294047
|
Phase 3 |
|
| 10 |
Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women |
Completed |
NCT01461096
|
Phase 3 |
|
| 11 |
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) |
Completed |
NCT00543543
|
Phase 3 |
|
| 12 |
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) |
Completed |
NCT00090220
|
Phase 3 |
|
| 13 |
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) |
Completed |
NCT00092547
|
Phase 3 |
|
| 14 |
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) |
Active, not recruiting |
NCT03493542
|
Phase 3 |
|
| 15 |
Safety and Immunogenicity Study of V503 (GARDASILâ„¢9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam |
Active, not recruiting |
NCT03546842
|
Phase 3 |
|
| 16 |
Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion |
Not yet recruiting |
NCT02011997
|
Phase 3 |
|
| 17 |
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) |
Completed |
NCT00365716
|
Phase 2 |
|
| 18 |
V501 Efficacy Study in Women Aged 18 to 26 (V501-027) |
Completed |
NCT00378560
|
Phase 2 |
|
| 19 |
Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil |
Completed |
NCT00518336
|
Phase 2 |
|
| 20 |
Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer |
Recruiting |
NCT03053544
|
Phase 2 |
Metformin |
| 21 |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
Recruiting |
NCT02834013
|
Phase 2 |
|
| 22 |
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer |
Active, not recruiting |
NCT01696877
|
Phase 1, Phase 2 |
degarelix acetate;Cyclophosphamide;GVAX |
| 23 |
Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease |
Completed |
NCT00709891
|
Not Applicable |
|
| 24 |
Randomized Controlled Trial of Human Papillomavirus Testing in Primary Cervical Cancer Screening |
Completed |
NCT00479375
|
Not Applicable |
|
| 25 |
Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study |
Completed |
NCT02323997
|
|
|
| 26 |
In the Era of the HPV Vaccine, What Are The Current HPV Subtypes Contributing to High Grade Cervical Dysplasia, Adenocarcinoma in Situ, and Early Cervical Cancer? |
Recruiting |
NCT02937155
|
|
|
| 27 |
A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects |
Recruiting |
NCT03438006
|
|
|
| 28 |
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer |
Recruiting |
NCT02140021
|
Not Applicable |
|
| 29 |
Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix |
Active, not recruiting |
NCT02206048
|
Not Applicable |
Proflavine |
| 30 |
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) |
Active, not recruiting |
NCT02653118
|
|
|
| 31 |
Treatment of Multifocal Lung Adenocarcinoma |
Active, not recruiting |
NCT01946100
|
Not Applicable |
|
| 32 |
Evaluation of Long-term HPV Vaccine Efficacy |
Enrolling by invitation |
NCT01393470
|
|
|
| 33 |
A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing |
Enrolling by invitation |
NCT02705404
|
|
|
| 34 |
Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC |
Not yet recruiting |
NCT03216551
|
|
|
| 35 |
Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer |
Suspended |
NCT02574442
|
|
|
|
